BPNT1 Inhibitors
BPNT1 inhibitors are a class of chemical compounds that specifically target and interact with the enzyme known as BPNT1, which stands for Bisphosphate Nucleotidase 1. BPNT1 is an essential enzyme involved in various cellular processes, primarily related to the metabolism and regulation of nucleotides within cells. These inhibitors are designed to modulate the activity of BPNT1, often by binding to its active site or other functional regions, thereby altering its function and activity within the cell.
The primary role of BPNT1 in the cell is to hydrolyze bisphosphorylated nucleotides, such as adenosine 5'-diphosphate (ADP) and guanosine 5'-diphosphate (GDP), into their respective monophosphate forms (AMP and GMP). This enzymatic activity plays a crucial role in maintaining the balance of nucleotides within the cell and is involved in various cellular processes, including nucleotide salvage pathways, purine metabolism, and nucleic acid synthesis. By inhibiting BPNT1, these compounds can disrupt these processes and potentially have important implications for cellular function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ticagrelor | 274693-27-5 | sc-472972 sc-472972A sc-472972B sc-472972C | 10 mg 25 mg 50 mg 100 mg | $104.00 $228.00 $270.00 $302.00 | ||
Ticagrelor inhibits BPT1 by binding to the P2Y12 receptor on platelets, preventing ADP-mediated platelet activation and aggregation, ultimately reducing thrombus formation. | ||||||
Prasugrel | 150322-43-3 | sc-391536 | 100 mg | $79.00 | ||
Prasugrel is another P2Y12 receptor antagonist that inhibits BPT1 by preventing platelet activation and aggregation, thereby reducing thrombotic events. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole inhibits BPT1 by increasing intracellular levels of cAMP, which inhibits platelet activation and aggregation through multiple mechanisms. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $158.00 | 18 | |
Rivaroxaban is a direct Factor Xa inhibitor that disrupts the coagulation cascade, preventing the formation of fibrin and reducing clot formation. | ||||||
Apixaban | 503612-47-3 | sc-364406 sc-364406A | 10 mg 50 mg | $240.00 $634.00 | 2 | |
Apixaban is another direct Factor Xa inhibitor that reduces thrombus formation by inhibiting the conversion of prothrombin to thrombin. | ||||||
Edoxaban | 480449-70-5 | sc-483508 | 25 mg | $522.00 | ||
Edoxaban inhibits BPT1 by directly targeting Factor Xa, interfering with the coagulation cascade and preventing clot formation. | ||||||
Argatroban | 74863-84-6 | sc-201310 sc-201310A | 10 mg 50 mg | $117.00 $469.00 | 13 | |
Argatroban is a direct thrombin inhibitor that prevents the conversion of fibrinogen to fibrin, ultimately reducing clot formation. | ||||||
Dabigatran | 211914-51-1 | sc-481166 | 5 mg | $205.00 | 1 | |
Dabigatran is another direct thrombin inhibitor that inhibits the formation of fibrin clots by targeting thrombin directly. | ||||||
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | $73.00 $246.00 | 7 | |
Warfarin interferes with the synthesis of clotting factors II, VII, IX, and X by inhibiting the enzyme vitamin K epoxide reductase, reducing clot formation. | ||||||
Fondaparinux | 104993-28-4 | sc-507424 | 10 mg | $297.00 | ||
Fondaparinux indirectly inhibits BPT1 by targeting Factor Xa via its antithrombin III-binding domain, preventing thrombin formation. | ||||||